Skip to main content
PLOS One logoLink to PLOS One
. 2026 Feb 13;21(2):e0338930. doi: 10.1371/journal.pone.0338930

Trends and age-period-cohort analysis of migraine incidence in China from 1990 to 2021

Yuting Huang 1,#, Dongxue Liu 1,#, Hongxiao Zhang 1,‡, Xufang Xu 1,‡, Shuangshuang Yuan 1, Shaoyang Cui 1, Zhihua Peng 1,*, Run Zhang 1
Editor: Pengpeng Ye2
PMCID: PMC12904424  PMID: 41686788

Abstract

Objective

The rapid economic development and demographic changes in Chinese society in the past 30 years may affect the prevalence of migraine. However, there are limited studies on the long-term trends and influencing factors of migraine burden in China. Using data from global burden of disease database (GBD2021), this study explores the changes in the migraine burden in China over a 30-year period and analyzes the main drivers.

Methods

Joinpoint regression analysis was used to evaluate the temporal trend of migraine prevalence, incidence, and years lived with disability (YLDs), and the age-period-cohort (APC) model was used to evaluate the effects of age, time and birth cohort. Decomposition analysis were used to calculate the contribution of population growth, ageing, and epidemiological changes to the burden of disease.

Results

In the past 30 years, the age-standardized prevalence rate (ASPR) and YLDs rate of migraine in China have increased significantly, and the disease burden of women is higher than that of men, especially in people aged 30–54 years. The main driver of the rising burden of disease is population growth. APC analysis showed that the younger generation had a higher burden of disease, which may be related to modern lifestyles and stressors.

Conclusion

The burden of migraine continues to increase in China, which is mainly affected by population growth and epidemiological changes. In the future, attention should be paid to high-risk groups, and lifestyle interventions and disease management should be strengthened to reduce the socio-economic burden.

Introduction

Migraine is a very common neurovascular problem. It is characterized by repeated attacks, causing moderate to severe headaches, and recoverable neurological symptoms, such as photophobia, phonophobia, allodynia, nausea and dizziness. Almost one-third of patients will have temporary neurological phenomena, the most common of which is visual. These phenomena may occur before or during the headache, or independently of the headache [1]. Migraine often appears with psychological problems such as anxiety and depression, and it is also related to other physical problems, such as poor metabolism—especially insulin resistance and obesity [2]—and it is also closely related to cardiovascular diseases such as hypertension and stroke [3,4]. The range of associated comorbidities emphasizes that migraine transcends a purely neurological disorder, representing a systemic condition with significant clinical and public health relevance [5]. On a global scale, migraine is the second-ranked disabling disease, and it is the primary cause of female disability [6], but its prevalence varies greatly in different regions and populations [7]. Wider social and lifestyle changes-including more and more sedentary jobs, rising stress levels, changing eating habits to Western diet featuring high-sugar foods and processed foods, and increasing dependence on electronic devices-have been identified as potential triggers of migraine risk in previous studies. These factors may provide a meaningful background for us to understand the increasing global migraine burden, and point out the important direction of future empirical research [8]. The incidence of migraine, that is, the number of new cases, can more accurately reflect the change of risk over time than the total number of patients. Although this is very important for making preventive measures and policy planning, the continuous monitoring of migraine incidence in China is still insufficient. Many studies around the world have discussed the burden of migraine, few studies can make a detailed analysis according to the characteristics of these people, such as age, gender or birth year [7]. Moreover, the scope and methods of our existing Chinese research are very narrow, which makes it difficult for us to accurately judge the long-term development trend [9–11]. Many studies conflate incidence, prevalence, and YLDs, potentially undermining epidemiological clarity. Therefore, the present study seeks to fill these research gaps by analyzing migraine incidence, prevalence, and YLDs in China from 1990 to 2021, employing Joinpoint regression, age–period–cohort modeling, and decomposition analysis to improve interpretability across demographic groups.

Methods

Data sources

Our research uses the data of GBD 2021. GBD 2021 provides the latest estimates of diseases and injuries in 21 disease-burden regions and 204 countries and regions from 1990 to 2021. All the data can be found publicly on the website of Global Health Data Exchange (https://vizhub.healthdata.org/gbd-results/). In GBD 2021, migraine was defined in accordance with the diagnostic criteria outlined in the International Classification of Headache Disorders, third edition (ICHD-3) [12], without differentiating between migraine with and without aura. For us in China, the input data comes from many places, including door-to-door population surveys, registration offices dedicated to recording certain diseases, and medical system databases, such as hospital records and medical insurance reimbursement lists [6,13]. The estimates were produced using the DisMod-MR 2.1 Bayesian meta-regression framework, which integrates heterogeneous data sources, enforces standardized case definitions, adjusts for recognized biases, and quantifies uncertainty through 95% uncertainty intervals [6]. This study utilized data on migraine-related indicators—prevalence, incidence, and YLDs—disaggregated by sex for China between 1990 and 2021. While modeled estimates enable extensive temporal analyses, discrepancies from observed diagnoses may arise due to heterogeneity in input sources and modeling parameters.

Statistical analysis

Descriptive analysis.

Data were organized and preprocessed in Microsoft Excel 2019. Summary statistics described the number of migraine cases and the age-standardized incidence, prevalence, and YLDs rates across different demographic groups. Visualization and graphical analyses were completed using R software (version 4.4.1).

Joinpoint regression analysis.

Joinpoint regression was employed to assess temporal trends in the burden of migraine. The Annual Percent Change (APC), Average Annual Percent Change (AAPC), and their corresponding 95% Confidence Intervals (CI) were computed using Joinpoint software. An annual percent change > 0 was interpreted as an increasing trend, while an annual percent change < 0 was interpreted as a decreasing trend during the given time interval.

Decomposition analysis.

We used a powerful analysis method in R software (version 4.4.1) to calculate how population growth, aging people and changes in disease patterns affected migraine burden from 1990 to 2021. As the previous study [14] said, this method can separate the influence of population structure from the influence of different ages and gender incidence changes. The total change in cases or rates (ΔY) was expressed as the aggregation of three components:

ΔY=Mp +Ma+Mm,

where Mp represents the contribution of population growth, Ma reflects the contribution of population ageing (i.e., changes in age structure), and Mm captures epidemiological change, defined as shifts in age- and sex-specific incidence, prevalence, or YLDs rates after controlling for population size and age structure. The detailed mathematical formulation of the decomposition model, including the definition of interaction terms and their allocation, is provided in S1 File.

Age-period-cohort analysis.

Age–Period–Cohort (APC) analysis in this study was conducted using the Biowinford online platform (http://biowinford.site:3838/trial/), which implements the constraint-based Holford identification method to resolve the intrinsic linear dependency among age, period, and cohort effects by imposing parameter constraints on period and cohort terms. Although the platform does not provide conventional diagnostics such as AIC, BIC, or residual analysis, this does not compromise methodological robustness, because likelihood-based information criteria are not applicable under APC’s exact linear dependency structure—an established property documented in foundational APC methodological work [15]. The identification strategy used in Biowinford is identical to that of the NIH APC Web Tool (https://analysistools.cancer.gov/apc/), and the Holford estimable-function framework has undergone extensive validation across epidemiologic and demographic research. Empirical applications consistently demonstrate stable and reproducible age, period, and cohort trend estimates across large population datasets, supporting the reliability of APC results even in the absence of traditional diagnostics [16,17]. Accordingly, the consistency of our analytical framework with validated APC methodology, as well as the stable patterns observed in our estimable functions, supports the interpretability and robustness of the temporal trends reported in this study.

Results

Descriptive analysis

In 2021, the total number of migraine cases in China reached 184,752,280, comprising 7,003,623 males and 11,471,057 females (Table 1). Among these, 13,047,221 were new cases, with 4,965,958 in males and 8,081,262 in females. The total YLDs due to migraine amounted to 6,988,199, including 2,745,321 in males and 4,242,878 in females. The age-standardized prevalence rate of migraine was 11,777.5 per 100,000 population, with 8,782 in males and 14,959 in females. The incidence rate was 976 per 100,000 population, with 722.2 in males and 1,252.7 in females. The YLDs rate was 443.7 per 100,000 population, with 341.3 in males and 552.7 in females. Migraine was most common between ages 30–54, peaking in females aged 35–44. Age-standardized incidence began rising from 5–9 years and peaked at 30–39 years. The YLDs burden was highest in the 30–49 age group, with females experiencing a notably greater burden than males (Fig 1).

Table 1. Migraine cases and age-standardized prevalence, incidence, and Years Lived with Disability rate in all age groups in China in 2021.

All-ages cases Age-standardized rate per 100000 people
Measure Total Male Female Total Male Female
Prevalence 184752280 (160836525,213633958) 70036223 (60652046,81324228) 114716057 (98856231,132076638) 11777.5 (10137.6,13538.6) 8782.0 (7497.4,10129.3) 14959.0 (12857.8,17190.4)
Incidence 13047221 (11597731,14698852) 4965958 (4347456,5638305) 8081262 (7209929,9102490) 975.6 (862.3,1102.1) 722.2 (629.1,825.0) 1252.7 (1112.5,1403.9)
YLDs (Years Lived with Disability) 6988199 (1133319,15186289) 2745321 (581677,5851443) 4242878 (548620,9335915) 443.7 (66.9,971.7) 341.3 (67.7,739.2) 552.7 (64.7,1221.5)

Incidence: The occurrence of new migraine cases and captures temporal shifts in risk more directly than prevalence. Prevalence: The total number of existing cases at a specific time, reflecting the population burden. YLDs: Years lived with disability.

Fig 1. Age-specific counts and age-standardized prevalence, incidence, and YLDs of migraine in China in 2021.

Fig 1

(A) Prevalence in specific age groups. (B) Age-standardized prevalence. (C) Incidence in specific age groups. (D) Age-standardized incidence. (E) YLDS in specific age groups. (F) Age-standardized YLDS. incidence rose from early childhood (5-9 years), peaked in the 30-39 age group, and declined after age 60, with females consistently showing a higher burden than males.

Joinpoint regression analysis

Joinpoint regression analysis of age-standardized incidence (ASIR), prevalence (ASPR), and YLDs (ASYR) rates for migraine in China from 1990 to 2021 (Table 2) revealed dynamic trends. Both ASIR and ASPR declined from 1996–2000, with annual percent changes of −0.33% and −0.42%, respectively, increased sharply from 2000–2005 (1.00% and 1.19%), slowed during 2005–2016 (0.05% and 0.07%), accelerated in 2016–2019 (0.78% and 0.73%), and slightly changed in 2019–2021 (−0.16% and 0.12%). Gender-stratified analysis showed similar patterns, with females exhibiting marginally faster growth; male AAPC in incidence was 0.25% versus 0.18% in females, and overall ASPR AAPC was 0.23%. YLDs followed comparable temporal trends: decline (1996–2000), rise (2000–2005), plateau (2005–2016), acceleration (2016–2019), and slight decrease (2019–2021). Growth in YLDs was similar across genders (AAPC 0.24%), with females showing a slightly higher rate. These results indicate that migraine burden in China has fluctuated over three decades, with recent periods showing modest but consistent increases, particularly among females.

Table 2. Trends in the joint regression analysis of age-standardized incidence rates, prevalence rates, and years lived with disability rates for all genders, men and women in China from 1990 to 2021.

Gender ASIR ASRP ASYR
Period APC(95%CI) AAPC(95%CI) Period APC(95%CI) AAPC(95%CI) Period APC(95%CI) AAPC(95%CI)
Both 1990-1996 −0.03 (−0.08 ~ −0.02) 0.20 (0.16 ~ 0.24) 1990-1996 −0.02 (−0.08 ~ 0.04) 0.23 (0.19 ~ 0.28) 1990-1996 0.01 (−0.06 ~ 0.08) 0.23 (0.18 ~ 0.29)
1996-2000 −0.33 (−0.47 ~ −0.19) 1996-2000 −0.42 (−0.59 ~ −0.25) 1996-2000 −0.50 (−0.69 ~ −0.30)
2000-2005 1.00 (0.91 ~ 1.10) 2000-2005 1.19 (1.09 ~ 1.30) 2000-2005 1.19 (1.06 ~ 1.32)
2005-2016 0.05 (0.03 ~ 0.08) 2005-2016 0.06 (0.04 ~ 0.09) 2005-2016 0.07 (0.04 ~ 0.10)
2016-2019 0.78 (0.50 ~ 1.07) 2016-2019 0.87 (0.53 ~ 1.21) 2016-2019 0.73 (0.33 ~ 1.14)
2019-2021 −0.16 (−0.44 ~ 0.13) 2019-2021 −0.07 (−0.42 ~ 0.28) 2019-2021 0.12 (−0.28 ~ 0.52)
Male 1990-1996 −0.02 (−0.09 ~ 0.04) 0.25 (0.20 ~ 0.30) 1990-1996 −0.02 (−0.06 ~ 0.03) 0.27 (0.24 ~ 0.30) 1990-1996 0.08 (−0.01 ~ 0.17) 0.24 (0.20 ~ 0.29)
1996-2000 −0.36 (−0.54 ~ −0.18) 1996-2000 −0.39 (−0.51 ~ 0.27) 1996-2000 −0.49 (−0.61 ~ −0.36)
2000-2005 1.00 (0.89 ~ 1.12) 2000-2005 1.09 (1.01 ~ 1.17) 2000-2005 1.17 (1.05 ~ 1.30)
2005-2016 0.10 (0.07 ~ 0.13) 2005-2016 0.04 (0.02 ~ 0.06) 2005-2016 0.20 (0.01 ~ 0.40)
2016-2019 1.17 (0.79 ~ 1.56) 2016-2019 1.04 (0.91 ~ 1.17) 2016-2019 0.00 (−0.09 ~ 0.09)
2019-2021 −0.17 (−0.56 ~ 0.22) 2019-2021 0.02 (−0.23 ~ 0.28) 2019-2021 0.45 (0.38 ~ 0.52)
Female 1990-1996 −0.02 (−0.06 ~ 0.01) 0.18 (0.15 ~ 0.21) 1990-1996 −0.03 (−0.08 ~ 0.03) 0.21 (0.17 ~ 0.26) 1990-1996 0.00 (−0.06 ~ 0.05) 0.24 (0.19 ~ 0.28)
1996-2000 −0.34 (−0.45 ~ 0.24) 1996-2000 −0.50 (−0.65 ~ −0.35) 1996-2000 −0.43 (−0.58 ~ −0.27)
2000-2005 0.99 (0.92 ~ 1.05) 2000-2005 1.22 (1.12 ~ 1.32) 2000-2005 1.03 (0.92 ~ 1.13)
2005-2016 0.05 (0.03 ~ 0.07) 2005-2016 0.06 (0.04 ~ 0.09) 2005-2016 0.07 (0.04 ~ 0.09)
2016-2019 0.62 (0.42 ~ 0.82) 2016-2019 0.68 (0.37 ~ 0.98) 2016-2019 1.12 (0.80 ~ 1.45)
2019-2021 −0.09 (−0.29 ~ 0.11) 2019-2021 0.02 (−0.29 ~ 0.33) 2019-2021 0.03 (−0.29 ~ 0.35)

APC: Annual Percentage Change; AAPC: Average Annual Percentage Change; ASIR: Age-Standardized Incidence Rate; ASPR: Age-Standardized Prevalence Rate; ASYR: Age-Standardized YLDs Rate.

Decomposition analysis

The decomposition analysis results (Fig 2) show that population growth was the dominant driver of the increasing burden of migraine in China. In both males and females, the contribution of population growth to incidence, prevalence, and YLDs was consistently large and nearly identical (Fig 2A–C). In contrast, the impact of population aging was relatively limited, exerting only modest effects on prevalence (Fig 2B) and YLDs (Fig 2C). Epidemiological change—defined as variation in age- and sex-specific incidence, prevalence, or YLDs after accounting for changes in population size and structure—also contributed to the observed increases. Its effect was moderate compared with demographic drivers, but was more noticeable in females, particularly for YLDs (Fig 2C). Overall, these results highlight that population growth is the primary determinant of migraine burden, while aging has only a minor effect, and epidemiological changes have contributed additionally, especially among women.

Fig 2. Population level determinants of population growth, aging and epidemiological changes in Chinese from 1990 to 20221 on migraine incidence.

Fig 2

(A) Contribution of population growth, aging, and epidemiological change to migraine incidence. (B) Contribution of population growth, aging, and epidemiological change to migraine prevalence. (C) Contribution of population growth, aging, and epidemiological change to YLDs rate. Population growth was the major driver of increasing incidence, while aging had limited impact. Epidemiological changes contributed modestly, with stronger effects observed among females.

Age-period-cohort analysis

Age effect analysis reveals that the YLDs rate of migraine exhibits age-related variations (Fig 3, left column). The period effect reflects the temporal trend in migraine burden (Fig 3, middle column). According to the results of this study, between 1990 and 2005, the YLDs rate for migraine remained relatively stable; however, after 2005, an overall upward trend emerged, which became particularly pronounced after 2010. The period effect in females showed a significantly faster increase compared to males. The cohort effect reflects the changes in migraine burden across different birth cohorts (Fig 3, right column). The analysis indicates that more recently born cohorts (post-1990) exhibit an increasing trend in migraine YLDS compared to earlier birth cohorts.

Fig 3. Effects of age, period, and cohort on the rate of YLDs in migraine.

Fig 3

The age effect showed the heaviest burden in young and middle-aged adults, the period effect indicated rising YLDS after 2005, and the cohort effect revealed higher burdens in more recent birth cohorts, especially post-1990.

Discussion

People with migraine are more likely to encounter difficulties in life and their quality of life is more likely to deteriorate than those without headaches [18]. The burden brought by migraine is obviously different among people of different regions, sexes and levels of Socio-Demographic Index (SDI) [19]. These differences are closely related to population growth, aging, urbanization and lifestyle changes [20].

In order to find out the temporal trend of migraine burden, we analyzed the long-term data in different historical periods. From the mid-1990s to the early 2000s, the incidence and prevalence of migraine decreased slightly, which may be due to the problems of insufficient diagnosis and frequent misdiagnosis in primary health care, where the diagnostic accuracy was only 13%–18%, and people seldom used drugs such as triptans at that time [21]. Specific drugs for migraine, such as triptans, are few in number, which makes many people reluctant to see a doctor. Among all acute treatment drugs, the prescription of these specific drugs is less than 3.3%, and it is especially difficult to find them in rural clinics [22]. With our country's more and more understanding of migraine, the age-adjusted incidence and prevalence rate began to rise again between 2000 and 2005. This situation may be due to the popularization of clinical guidelines and the use of triptan therapy, which has brought some slow improvement [23], although direct supporting evidence remains limited. From 2016 to 2019, we see that the growth rate has become faster again, which is just the time when the “Healthy China 2030” initiative began to be implemented. The plan pays special attention to making more people enjoy medical services and increases the services of specialists. From 2019 to 2021, the data decreased slightly, which is probably due to the influence of COVID-19 epidemic. During that time, the number of people going to the hospital outpatient service decreased obviously. Although the number of people who see online doctors has increased, the accuracy of online diagnosis is not so high, so the data we see has decreased, which may not be that there are fewer migraine patients, but that some cases have not been recorded [24].

The results of this study tell us that the incidence of migraine begins to increase from the age of 5–9, reaches its peak at the age of 35–44, and then gradually decreases. The highest incidence rate is among people aged 30–54, and it will drop significantly after 60 years old. Therefore, migraine mainly bothers young people and middle-aged people. We also found a big difference between men and women. The burden of illness of women is much heavier than that of men [25]. These sex- and age-related variations in migraine burden can be explained by well-established neurobiological mechanisms [26].

Trigeminovascular pathway plays a central role in migraine attack. This pathway originated from the sensory neurons in the trigger ganglion, and their peripheral branches connected with intracranial blood vessels and dura mater, while the central part extended to the trigger nucleus caudalis in the brain stem. When these afferent fibers are activated, calcitonin gene-related peptide (CGRP) and other neuropeptides will be released in meningeal blood vessels, leading to vasodilation, plasma protein exudation and mast cell degranulation [26,27]. Together, these mechanisms inflame our nerves, so the pain signal spreads even more. In this way, the trigeminal nerve becomes particularly sensitive, so that those “pain signals” are constantly transmitted to the brain stem and cerebral cortex, so the headache can not be cured. Sex hormones-especially Estrogen-can also affect this process. Estrogen can affect CGRP signal in many ways, for example, it can promote gene transcription, help peptide release, and increase the number of receptor CLR and RAMP1 [28,29]. It also affects migraine-related neurotransmission by regulating serotonin and glutamate activity [12,30,31]. The changes in estrogen levels in our bodies can explain why migraines increase in adolescence, become the most severe in young adults, and then decrease after menopause. Monoclonal antibodies and small molecular antagonists that specifically deal with CGRP- trigeminal neurovascular pathway are really useful in clinic, which tells us that this pathway is super important in the process of migraine [32]. This effect can help us understand why migraine becomes significantly more common after puberty and why many women report that migraine is often related to menstruation. They also make us understand that the therapeutic effect will vary with gender, for example, women may have different reactions to CGRP-targeted interventions. Although females presently bear a higher migraine burden, demographic projections suggest that by 2050, the rates of increase in incidence, prevalence, and Disability-Adjusted Life Years (DALYs) among males will exceed those in females [33]. This may reflect higher work stress and limited health awareness among men [33], cultural barriers to reporting and treatment [34], and insufficient help-seeking [35], underscoring the need to reconsider migraine as a “female disease” [19] and to strengthen male-focused prevention and early intervention [7].

Another pivotal mechanism involved in migraine pathophysiology is cortical spreading depression (CSD), characterized by a slowly advancing wave of neuronal and glial depolarization followed by a sustained suppression of cortical activity. CSD is widely recognized as the electrophysiological basis underlying the migraine aura [36]. By disturbing the ion balance in our body, and letting some exciting signal substances such as glutamate and potassium escape, CSD will activate the pain receptors on the meninges through a system called trigeminovascular, thus establishing a connection between cerebral cortex overexcitation and headache onset [37]. Patients with migraine with aura may not only have special symptoms, such as blurred vision or abnormal sensation before headache, but also face higher long-term cerebrovascular risk. This is because CSD is thought to destroy blood-brain barrier and increase the risk of stroke [38,39]. This mechanistic framework explains why cortical hyperexcitability is not merely an epiphenomenon but an active contributor to both the phenotype and comorbid risks of migraine.

In addition to adult patterns, our findings revealed that migraine incidence can rise as early as 5–9 years of age. Consistent with this, Meng et al. reported that many cases actually begin in childhood or adolescence [40], with prevalence reaching 7–10% among school-aged children and up to 20% in adolescents [41]. However, children's migraine is often not found by doctors. Because it is often not the kind of headache that we usually know, but it will turn into a strange appearance such as stomachache, cyclic violence, or sudden dizziness [42]. Recognizing these atypical manifestations is crucial for achieving timely diagnosis and reducing the burden associated with inadequately treated childhood migraine. Headache disorders that emerge during adolescence may persist or even worsen over time, potentially developing into chronic and refractory forms that impose substantial burdens on both individuals and society [32]. Environmental triggers such as academic stress, sleep deprivation, and excessive electronic device use further exacerbate the risk of migraine onset in children and adolescents [43], with excessive device use identified as a significant factor [44]. Migraine is the leading cause of health loss between ages 15 and 49 [45], and onset typically occurs before 18, challenging the prior view of adult onset [46]. The age range of 15–39 is critical for education, career, and social development, with heightened susceptibility [47], while individuals aged 35–44 face dual career and family pressures contributing to peak prevalence and YLDs[7]. As global aging accelerates, children and adolescents will remain a key demographic, requiring targeted prevention and treatment to reduce social and economic burdens [40]. Young and middle-aged patients are also disproportionately affected by stigmatization, necessitating improved awareness, patient dignity, and policy interventions [48].

Baidu Index data shows that “how to quickly and effectively treat migraine” is the most searched migraine problem, which shows that patients are most concerned about how to control symptoms and treat themselves [49]. In China, the condition of seeing a doctor and treating migraine is not good enough: only 26.4% of patients get acute drugs, 15% take preventive treatment, and about 40% never see a doctor [50]. This situation tells us that we urgently need to improve the diagnostic ability of doctors, make it easier for patients to get treatment, and strengthen everyone's health knowledge education.

With the increasing burden of migraine in China, it will bring more and more pressure to our medical system and social economy, which reminds us to find this problem early and deal with it well. It is very important to take targeted measures according to everyone's age, gender, SDI index and different symptoms, and to ensure that everyone can get medical services fairly [19]. ailor-made public health strategies can help alleviate chronic pain [47], while pain knowledge education through various channels can improve people's understanding and self-management ability [51]. It is very important to establish a comprehensive system integrating education, primary care, professional training and effect evaluation to realize long-term control [19].

Limitations

Several limitations should be acknowledged in this study. First, all estimates were generated from the Global Burden of Disease (GBD) database, which, although incorporating Chinese data sources—surveys, registries, hospital records, and insurance claims—relies on statistical modeling rather than direct data analysis. As a result, the outcomes may not precisely represent primary national data, and biases arising from input quality or model specification could yield systematic error. Therefore, these results may not fully represent the real situation of our country, and if the quality of input data is not good or the model setting is problematic, systematic errors may occur. Second, some cases may not be correctly recorded or classified by doctors, especially in rural areas, and among men who are not convenient to see a doctor. Third, our analysis did not take into account the huge differences between different places, cities and rural areas, and between the rich and the poor in China. Because we did not study these differences carefully, the results may be biased. Fourthly, some important factors, such as the change of people's living habits, air pollution and urbanization, are not included in the analysis. Finally, the age–period–cohort model, while useful for exploring temporal dynamics, relies on assumptions that constrain causal interpretation. So when we look at our research results, we should remember these imperfections, which also shows that we need to test and expand our findings with more detailed clinical data from more people in the future.

Conclusion

Drawing on data from the GBD2021 database, this study provides a systematic evaluation of long-term migraine burden trends in China. Across the past three decades, age-standardized prevalence and YLDs rates have increased markedly, especially among adults aged 30–54, with females experiencing a disproportionately higher impact. It is found that the increase of population is the main reason, and the change of disease pattern is the second reason, and the influence of population aging is relatively small. Age–period–Cohort analysis also found that the younger generation bears a heavier relative burden. Generally speaking, these findings tell us that it is necessary to formulate age and gender-sensitive measures for high-risk groups to alleviate the long-term health problems and socio-economic impact of migraine. Future research should continue to investigate the drivers of migraine burden more deeply and evaluate the effects of those targeted measures.

Supporting information

S1 File. The Decomposition Method.

This file provides the step-by-step description of the decomposition approach used to attribute changes in migraine incidence, prevalence, and YLDs to population growth, population ageing, and epidemiological change.

(DOCX)s

pone.0338930.s001.docx (30.7KB, docx)
S2 File. Raw Data.

This file contains the dataset used for calculating the incidence, prevalence, and YLDs of migraine in China, as well as the corresponding inputs for the decomposition and age-period-cohort analyses.

(ZIP)

pone.0338930.s002.zip (437.8KB, zip)

Acknowledgments

We thank the Institute for Health Metrics and Evaluation (IHME) for providing access to the Global Burden of Disease Study 2021 (GBD 2021) data, which formed the basis of our analyses. We also acknowledge all researchers and institutions involved in the collection, curation, and maintenance of the GBD 2021 dataset, whose efforts have enabled global health research such as the present study.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Dodick DW. Migraine. Lancet. 2018;391(10127):1315–30. doi: 10.1016/S0140-6736(18)30478-1 [DOI] [PubMed] [Google Scholar]
  • 2.Del Moro L, Rota E, Pirovano E, Rainero I. Migraine, Brain Glucose Metabolism and the “Neuroenergetic” Hypothesis: A Scoping Review. J Pain. 2022;23(8):1294–317. doi: 10.1016/j.jpain.2022.02.006 [DOI] [PubMed] [Google Scholar]
  • 3.Guidetti D, Rota E, Morelli N, Immovilli P. Migraine and stroke: “vascular” comorbidity. Front Neurol. 2014;5:193. doi: 10.3389/fneur.2014.00193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010;74(8):628–35. doi: 10.1212/WNL.0b013e3181d0cc8b [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Caponnetto V, Deodato M, Robotti M, Koutsokera M, Pozzilli V, Galati C, et al. Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain. 2021;22(1):71. doi: 10.1186/s10194-021-01281-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344–81. doi: 10.1016/S1474-4422(24)00038-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D. The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region. Pain Ther. 2025;14(1):297–315. doi: 10.1007/s40122-024-00690-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Xu R, Zhang R, Dong L, Xu X, Fan X, Zhou J. An analysis of the burden of migraine and tension-type headache across the global, China, the United States, India and Japan. Front Pain Res (Lausanne). 2025;6:1539344. doi: 10.3389/fpain.2025.1539344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wang Y, Huang X, Yue S, Liu J, Li S, Ma H, et al. Secular Trends in the Incidence of Migraine in China from 1990 to 2019: A Joinpoint and Age-Period-Cohort Analysis. J Pain Res. 2022;15:137–46. doi: 10.2147/JPR.S337216 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fan Z, Kang J, Li W, Wang Z, Qiao H, Xu F. Trends in migraine incidence among women of childbearing age from 1990 to 2019 and the prediction for 2030: an analysis of national data in China. J Headache Pain. 2023;24(1):158. doi: 10.1186/s10194-023-01692-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Liu Z, Hu XH, Yang L, Qi JL, Liu JM, Wang LJ, et al. Burden of Headache Disorders in China and its Provinces, 1990-2021. Biomed Environ Sci. 2025;38(5):547–56. doi: 10.3967/bes2025.019 [DOI] [PubMed] [Google Scholar]
  • 12.Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F. Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain. 2024;25(1):96. doi: 10.1186/s10194-024-01798-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhao W, Chen Y, Tang Y, Du S, Lu X. Analysis of headache burden Chinese in the global context from 1990 to 2021. Front Neurol. 2025;16:1559028. doi: 10.3389/fneur.2025.1559028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zhu J, Li S, Li X, Wang L, Du L, Qiu Y. Impact of population ageing on cancer-related disability-adjusted life years: A global decomposition analysis. J Glob Health. 2024;14:04144. doi: 10.7189/jogh.14.04144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rosenberg PS, Anderson WF. Age-period-cohort models in cancer surveillance research: ready for prime time?. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1263–8. doi: 10.1158/1055-9965.EPI-11-0421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rosenberg PS, Check DP, Anderson WF. A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2296–302. doi: 10.1158/1055-9965.EPI-14-0300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Luo L, Hodges JS. Constraints in Random Effects Age-Period-Cohort Models. Sociol Methodol. 2020;50(1):276–317. doi: 10.1177/0081175020903348 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.R P, S C N, S H, K R. Migraine Disability, Quality of Life, and Its Predictors. Ann Neurosci. 2020;27(1):18–23. doi: 10.1177/0972753120929563 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Zhu M, Zhang J, Liang D, Qiu J, Fu Y, Zeng Z, et al. Global and regional trends and projections of chronic pain from 1990 to 2035: Analyses based on global burden of diseases study 2019. Br J Pain. 2025;19(2):125–37. doi: 10.1177/20494637241310697 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Xavier MKA, Pitangui ACR, Silva GRR, Oliveira VMAd, Beltrão NB, Araújo RCd. Prevalence of headache in adolescents and association with use of computer and videogames. Cien Saude Colet. 2015;20(11):3477–86. doi: 10.1590/1413-812320152011.19272014 [DOI] [PubMed] [Google Scholar]
  • 21.Liu H, Dong M, Liu K, Jia Z, Gui W, Cheng Y, et al. Status of diagnosis and preventative treatment for primary headache disorders: real-world data of unmet needs in China. J Headache Pain. 2023;24(1):119. doi: 10.1186/s10194-023-01654-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yu S, Zhang Y, Yao Y, Cao H. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain. 2020;21(1):53. doi: 10.1186/s10194-020-01117-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Li Z, Yong L, Chengchun S. Clinical application progress of triptan drugs in the treatment of migraine. Journal of Pharmaceutical Sciences of the People’s Liberation Army. 2012;28(06):551–3. [Google Scholar]
  • 24.Chen S, Zhang Z, Yang J, Wang J, Zhai X, Bärnighausen T, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. Lancet. 2020;395(10232):1305–14. doi: 10.1016/S0140-6736(20)30744-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22. doi: 10.1016/S0140-6736(20)30925-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017;97(2):553–622. doi: 10.1152/physrev.00034.2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019;59(5):659–81. doi: 10.1111/head.13529 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Maddahi A, Edvinsson JCA, Edvinsson L. Sex differences in expression of CGRP family of receptors and ligands in the rat trigeminal system. J Headache Pain. 2024;25(1):193. doi: 10.1186/s10194-024-01893-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Russell FA, King R, Smillie S-J, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099–142. doi: 10.1152/physrev.00034.2013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Chen ZF, Kong XM, Yang CH, Li XY, Guo H, Wang ZW. Global, regional, and national burden and trends of migraine among youths and young adults aged 15-39 years from 1990 to 2021: findings from the global burden of disease study 2021. J Headache Pain. 2024;25(1):131. 2024. doi: 10.1186/s10194-024-01832-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B, et al. Male and female sex hormones in primary headaches. J Headache Pain. 2018;19(1):117. doi: 10.1186/s10194-018-0922-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Labastida-Ramírez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, et al. Mode and site of action of therapies targeting CGRP signaling. J Headache Pain. 2023;24(1):125. doi: 10.1186/s10194-023-01644-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Affatato O, Miguet M, Schiöth HB, Mwinyi J. Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank. J Headache Pain. 2021;22(1):145. doi: 10.1186/s10194-021-01356-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Shields LBE, Seifert T, Shelton BJ, Plato BM. Testosterone levels in men with chronic migraine. Neurol Int. 2019;11(2):8079. doi: 10.4081/ni.2019.8079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87. doi: 10.1016/S1474-4422(16)30293-9 [DOI] [PubMed] [Google Scholar]
  • 36.Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117 ( Pt 1):199–210. doi: 10.1093/brain/117.1.199 [DOI] [PubMed] [Google Scholar]
  • 37.Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J Neurosci. 2010;30(26):8807–14. doi: 10.1523/JNEUROSCI.0511-10.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab. 2011;31(1):17–35. doi: 10.1038/jcbfm.2010.191 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004;113(10):1447–55. doi: 10.1172/JCI21227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Meng W, Sui L. Headache disorders: a persistent public health challenge for the under 50s. Front Neurol. 2024;15:1501749. doi: 10.3389/fneur.2024.1501749 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Onofri A, Pensato U, Rosignoli C, Wells-Gatnik W, Stanyer E, Ornello R, et al. Primary headache epidemiology in children and adolescents: a systematic review and meta-analysis. J Headache Pain. 2023;24(1):8. doi: 10.1186/s10194-023-01541-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Azmy DJ, Qualia CM. Review of Abdominal Migraine in Children. Gastroenterol Hepatol (N Y). 2020;16(12):632–9. [PMC free article] [PubMed] [Google Scholar]
  • 43.Berring-Uldum AA, Skovgaard LT, Miranda MJ, Debes NM. Education and Social Life: The Impact of Headache on Participation in Children and Adolescents Attending a Headache Clinic-A Case-Control Study. Pediatr Neurol. 2025;169:185–95. doi: 10.1016/j.pediatrneurol.2025.05.030 [DOI] [PubMed] [Google Scholar]
  • 44.Mortel D, Kawatu N, Steiner TJ, Saylor D. Barriers to headache care in low- and middle-income countries. eNeurologicalSci. 2022;29:100427. doi: 10.1016/j.ensci.2022.100427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. doi: 10.1186/s10194-020-01208-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Waliszewska-Prosół M, Straburzyński M, Czapińska-Ciepiela EK, Nowaczewska M, Gryglas-Dworak A, Budrewicz S. Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort : Results from ’Migraine in Poland’-a nationwide cross-sectional survey. J Headache Pain. 2023;24(1):40. doi: 10.1186/s10194-023-01575-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Li XY, Yang CH, Lv JJ, Liu H, Zhang LY, Yin MY, et al. Global, regional, and national epidemiology of migraine and tension-type headache in youths and young adults aged 15-39 years from 1990 to 2019: findings from the global burden of disease study 2019. J Headache Pain. 2023;24(1):126. 2023. doi: 10.1186/s10194-023-01659-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Ge R, Chang J, Cao Y. Headache disorders and relevant sex and socioeconomic patterns in adolescents and young adults across 204 countries and territories: an updated global analysis. J Headache Pain. 2023;24(1):110. doi: 10.1186/s10194-023-01648-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lin L, Zhu M, Qiu J, Li Q, Zheng J, Fu Y, et al. Spatiotemporal distribution of migraine in China: analyses based on baidu index. BMC Public Health. 2023;23(1):1958. doi: 10.1186/s12889-023-16909-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20(1):111. doi: 10.1186/s10194-019-1062-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Cho S-H, Kim Y-M, Lee J-H, Kim H-S, Song J-S. The trend of prevalence of pain in Korea from 2005 to 2016. Korean J Pain. 2020;33(4):352–8. doi: 10.3344/kjp.2020.33.4.352 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Pengpeng Ye

6 Aug 2025

Dear Dr. Huang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 20 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Pengpeng Ye

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf   and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please note that PLOS ONE has specific guidelines on code sharing for submissions in which author-generated code underpins the findings in the manuscript. In these cases, we expect all author-generated code to be made available without restrictions upon publication of the work. Please review our guidelines at https://journals.plos.org/plosone/s/materials-and-software-sharing#loc-sharing-code and ensure that your code is shared in a way that follows best practice and facilitates reproducibility and reuse.

3. We note that your Data Availability Statement is currently as follows: “All relevant data are within the manuscript and its Supporting Information files.”

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition ).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories .

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

4. Please upload a copy of Figure 1 to which you refer in your text on page 5. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

5. Please upload a copy of Figure 2 to which you refer in your text on page 8. If the figure is no longer to be included as part of the submission please remove all reference to it within the text

6. Please upload a copy of Figure 3 to which you refer in your text on page 10. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

7. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

8. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: As a clinical researcher specializing in headache medicine, I commend the authors for tackling a topic of global neurological and public health relevance. The analysis of migraine burden in China over a 30-year span using the GBD 2021 dataset, combined with Joinpoint and age-period-cohort (APC) methods, provides a valuable framework. However, several significant conceptual, methodological, and reporting issues need to be addressed to meet the scientific and editorial standards of PLOS ONE.

1. Strengths

Timely topic: migraine remains a leading cause of global disability, and long-term trend data from China are underrepresented in current literature.

Use of a robust, longitudinal database (GBD 2021).

Application of both Joinpoint regression and APC models enriches the temporal analysis.

Inclusion of gender-stratified findings enhances interpretability and clinical relevance.

2. Major Concerns and Required Revisions

A. Introduction Needs Strengthening

The introduction lacks critical context. It should:

Specify gaps in prior Chinese or GBD migraine trend analyses,

Clarify the motivation for focusing on incidence,

Briefly acknowledge limitations inherent in using modeled data.

Recommendation: Expand the introduction to articulate the scientific rationale and relevance of the research more clearly.

B. Terminological Confusion: Incidence, Prevalence, and YLDs

The manuscript frequently conflates incidence, prevalence, and YLDs. This undermines epidemiological clarity.

Recommendation: Clearly define each metric and apply terminology consistently.

C. Critical Omission: Definition of Migraine in GBD

The manuscript does not describe how migraine cases were defined in the GBD 2021 model. As migraine diagnosis is clinical and symptom-based (e.g., per ICHD-3), clarity is essential.

Recommendation: Specify:

Whether ICHD-2 or ICHD-3 was used,

The types of source data for China (e.g., surveys, claims),

How modeling handled case ascertainment and uncertainty,

The implications of using modeled incidence vs. observed diagnosis.

D. Insufficient Methodological Transparency in APC Modeling

There is no mention of how the APC identifiability problem was handled, nor are any diagnostics reported.

Recommendation: Provide:

Identification strategy (e.g., Holford, constraint-based),

Software used,

Model diagnostics (e.g., residual analysis, AIC/BIC, VIF).

E. Joinpoint Analysis Lacks Historical or Clinical Context

Timepoint changes (e.g., in 2000, 2005, 2016) are presented without connecting them to relevant clinical or policy developments in China.

Recommendation: Contextualize Joinpoint inflection years using historical changes in health policy, treatment availability (e.g., triptans, CGRP), or diagnostic practices.

F. Superficial Clinical Interpretation

Sex and age-related differences are discussed briefly, but without meaningful reference to pathophysiological mechanisms. Notably:

CGRP biology, trigeminovascular pathways, and cortical spreading depression are not mentioned.

The increase in incidence beginning at age 5–9 is not discussed in the context of pediatric migraine.

Recommendation: Enrich discussion with insights from headache neuroscience and pediatric migraine epidemiology.

G. Speculative Interpretations of Lifestyle Factors

Attributing trends to screen time, stress, and diet is speculative and not empirically tested.

Recommendation: Rephrase such points as hypotheses or broader societal factors, not study findings.

H. Missing Limitations Section

Most critically, the manuscript lacks any discussion of limitations, which is required by PLOS ONE.

Recommendation: Include a paragraph acknowledging:

Use of GBD-modeled data rather than clinical registries,

Potential for misclassification or underdiagnosis (especially in rural or male populations),

No geographic stratification within China,

Unmeasured confounders (e.g., urbanization, air pollution),

Constraints inherent in APC modeling.

3. Minor Comments

Language: Consider professional editing for grammar and sentence flow.

Figures: Simplify and ensure that legends clarify key trends.

Data sharing and ethical statements are appropriate.

Reviewer #2: Introduction:

1) Among migraine comorbidities, the authors should also mention metabolic conditions such as insulin resistance and obesity (Del Moro L, Rota E, Pirovano E, Rainero I. Migraine, Brain Glucose Metabolism and the "Neuroenergetic" Hypothesis: A Scoping Review. J Pain. 2022 Aug;23(8):1294–1317), as well as cardiovascular diseases (Guidetti D, Rota E, Morelli N, Immovilli P. Migraine and stroke: "vascular" comorbidity. Front Neurol. 2014 Oct 8;5:193; Bigal ME et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010 Feb 23;74(8):628–35).

2) I recommend replacing the phrase “high-fat and high-protein diets” with the more general term “Western diet”, as some studies have shown that ketogenic diets, which are high in fat, may actually reduce migraine frequency and severity. Conversely, growing evidence suggests that high-glycemic index foods are the main dietary contributors to increased migraine burden (Del Moro L, Rota E, Pirovano E, Rainero I. Migraine, Brain Glucose Metabolism and the "Neuroenergetic" Hypothesis: A Scoping Review. J Pain. 2022 Aug;23(8):1294–1317).

Methods:

3) Although the study provides insightful decomposition analyses illustrating the contribution of demographic and epidemiological factors to the migraine burden, the methodology is not explicitly described. No formal models, equations, or supplementary materials are provided to allow for replication or critical evaluation of the decomposition approach.

Results:

4) There is a discrepancy between the figures reported in the text and those in Table 1. For example, the text states “the total number of migraine cases in China was 18,475,280,” while Table 1 reports “184,752,280”.

5) Table 1 should be corrected: values should be reported with only one decimal place.

6) In the main text, epidemiological data should be rounded and reported without decimal places to improve clarity.

7) The concept of “epidemiological change” is vague and not adequately defined. The authors do not explain which variables were used to represent these changes or how they were measured.

Discussion:

8) The Limitations section should explicitly mention that the study relies entirely on modeled estimates from the Global Burden of Disease, without comparison to real-world national data (e.g., Chinese surveillance systems, hospital admissions, prescription databases). GBD estimates are derived from complex models and may overestimate or underestimate true values, especially in countries with limited high-quality local data. This could introduce uncontrolled systematic bias.

9) China is geographically and socioeconomically heterogeneous, but the study does not examine regional differences (e.g., by province), urban vs. rural settings, or socioeconomic strata. This is another potential source of bias that should be acknowledged.

10) The discussion section includes several topics that are only tangentially related to the study’s results, such as calcitonin gene-related peptide therapy, estrogen’s contribution, and the framing of migraine as a "female disease". These should be either removed or significantly reduced, as they are not directly supported by the findings of this study.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: Yes: Lorenzo Del Moro

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2026 Feb 13;21(2):e0338930. doi: 10.1371/journal.pone.0338930.r002

Author response to Decision Letter 1


27 Oct 2025

We sincerely thank the reviewers and the editor for their insightful and constructive comments. We have carefully revised the manuscript in accordance with all the suggestions and provided a detailed point-by-point response in the attached document. We believe these revisions have substantially improved the quality and clarity of the manuscript. If there are any additional points that require further modification, we would be very pleased to address them.

Attachment

Submitted filename: Author_Response_Letter.docx

pone.0338930.s004.docx (64.9KB, docx)

Decision Letter 1

Pengpeng Ye

14 Nov 2025

Dear Dr. Huang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Dec 29 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Pengpeng Ye

Academic Editor

PLOS ONE

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: Summary of Evaluation:

After reviewing the manuscript and the author's responses, the majority of the reviewer's concerns have been adequately addressed. The key changes have been effectively made, particularly in terms of clarifying the research gaps, the focus on incidence, and the modeling limitations. Below is my detailed evaluation:

Point-by-Point Comments:

1. Introduction Needs Strengthening (Point 1):

The revised introduction now clearly specifies the research gaps and the rationale for focusing on incidence rather than prevalence, and acknowledges the limitations of using modeled data.

Conclusion: Fully addressed.

2. Terminological Confusion (Point 2):

The definitions for incidence, prevalence, and YLDs are clearly provided, and the terminology is now applied consistently throughout the manuscript.

Conclusion: Fully addressed.

3. Definition of Migraine in GBD (Point 3):

The definition of migraine using ICHD-3 is now explicitly stated, along with details of the data sources for China (e.g., population surveys, registries, hospital records). The modeling approach (DisMod-MR 2.1) is also clearly explained.

Conclusion: Fully addressed.

4. Methodological Transparency in APC Modeling (Point 4):

The author has described the Holford method and the Biowinford platform used for APC modeling. However, the lack of diagnostics (e.g., AIC, BIC) is acknowledged but not fully explained.

Suggested Improvement: The author should further explain the impact of missing diagnostics on the robustness of the model and clarify how the Holford method is widely validated despite the lack of diagnostics.

Conclusion: Mostly addressed, but further clarification required.

5. Joinpoint Analysis Lacks Historical or Clinical Context (Point 5):

The author has successfully contextualized the Joinpoint inflection years with relevant historical and clinical factors, such as the Healthy China 2030 initiative and the availability of triptans.

Conclusion: Fully addressed.

6. Superficial Clinical Interpretation (Point 6):

Detailed explanations of CGRP, trigeminovascular pathways, and cortical spreading depression (CSD) are now included. The discussion of pediatric migraine and early onset is also well addressed.

Conclusion: Fully addressed.

7. Speculative Interpretations of Lifestyle Factors (Point 7):

The manuscript now correctly reframes lifestyle factors as potential hypotheses and societal factors rather than definitive findings.

Conclusion: Fully addressed.

8. Missing Limitations Section (Point 8):

A dedicated limitations section has been added, acknowledging key limitations related to the use of modeled data, potential misclassification, lack of geographic stratification, and APC model constraints.

Conclusion: Fully addressed.

9. Minor Comments (Point 9):

Language has been improved, figure legends are clearer, and data sharing and ethical statements are appropriate.

Conclusion: Fully addressed.

Reviewer #2: The authors have adequately addressed all the comments. I have no further recommendations before publication

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: Yes: Lorenzo Del Moro

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Feb 13;21(2):e0338930. doi: 10.1371/journal.pone.0338930.r004

Author response to Decision Letter 2


25 Nov 2025

Dear Reviewers,

I would like to express my sincere gratitude for your thoughtful and constructive feedback on our manuscript. I have thoroughly revised the manuscript in response to all of your comments, making the necessary changes to enhance the clarity and rigor of the work. The revised sections are highlighted in the revised manuscript with track changes.I noticed that the clarity of Fig. 1 in the final generated PDF file is not satisfactory. I have tried many methods to improve the clarity of Fig. 1 in the PDF, but the results have been unsatisfactory. I have separately uploaded Fig. 1 in TIFF format to the submission system and kindly request that the editor and reviewers review the JPG version I uploaded. I also respectfully ask that the manuscript not be rejected solely because Fig. 1 does not appear clearly in the PDF. If there are any further modifications or clarifications needed, I would be more than happy to make additional revisions and cooperate fully to ensure that the manuscript meets the journal's standards.

Thank you again for your time and invaluable input.

Best regards,

Yuting,Huang

First Author

On behalf of all authors

Attachment

Submitted filename: Response to Reviewers.docx

pone.0338930.s005.docx (20.1KB, docx)

Decision Letter 2

Pengpeng Ye

30 Nov 2025

Trends and age-period-cohort analysis of migraine incidence in China from 1990 to 2021

PONE-D-25-16628R2

Dear Dr. Huang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Pengpeng Ye

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

**********

Reviewer #1: All of my previously addressed points are satisfactorily resolved.

No remaining mandatory revisions.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

**********

Acceptance letter

Pengpeng Ye

PONE-D-25-16628R2

PLOS One

Dear Dr. Huang,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Pengpeng Ye

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. The Decomposition Method.

    This file provides the step-by-step description of the decomposition approach used to attribute changes in migraine incidence, prevalence, and YLDs to population growth, population ageing, and epidemiological change.

    (DOCX)s

    pone.0338930.s001.docx (30.7KB, docx)
    S2 File. Raw Data.

    This file contains the dataset used for calculating the incidence, prevalence, and YLDs of migraine in China, as well as the corresponding inputs for the decomposition and age-period-cohort analyses.

    (ZIP)

    pone.0338930.s002.zip (437.8KB, zip)
    Attachment

    Submitted filename: Author_Response_Letter.docx

    pone.0338930.s004.docx (64.9KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0338930.s005.docx (20.1KB, docx)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES